← All trials
NCT06905587
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2025
- Primary completion
- Dec 31, 2029
- Completion date
- Dec 31, 2029
- First posted
- Apr 1, 2025
- Last posted
- Apr 1, 2025
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Southern DenmarkLead sponsor
- Aalborg UniversityCollaborator
- University of Southern DenmarkOfficial
- University of Southern DenmarkCollaborator
- University of CopenhagenCollaborator
- Aarhus UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.